These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 11967633

  • 1. Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease.
    Smolnik R, Fischer S, Hagenah J, Kis B, Born J, Vieregge P.
    Psychopharmacology (Berl); 2002 Apr; 161(1):70-6. PubMed ID: 11967633
    [Abstract] [Full Text] [Related]

  • 2. Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons.
    Schreiber H, Stolz-Born G, Pietrowsky R, Kornhuber HH, Fehm HL, Born J.
    Biol Psychiatry; 1995 May 15; 37(10):702-12. PubMed ID: 7640325
    [Abstract] [Full Text] [Related]

  • 3. Repetitive intranasal administration of cholecystokinin potentiates its central nervous effects.
    Denecke H, Meyer F, Feldkamp J, Fritzen R, Pietrowsky R.
    Physiol Behav; 2004 Oct 30; 83(1):39-45. PubMed ID: 15501489
    [Abstract] [Full Text] [Related]

  • 4. Motor activation time in Parkinson's disease.
    Segura MJ, Bueri JA, Gandolfo CN, Simonetti DD, Herrera GA, Sica RE.
    Medicina (B Aires); 1995 Oct 30; 55(3):208-12. PubMed ID: 8544717
    [Abstract] [Full Text] [Related]

  • 5. Effects of stimulus-response compatibility on inhibitory processes in Parkinson's disease.
    Beste C, Dziobek I, Hielscher H, Willemssen R, Falkenstein M.
    Eur J Neurosci; 2009 Feb 30; 29(4):855-60. PubMed ID: 19200076
    [Abstract] [Full Text] [Related]

  • 6. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
    Scholtissen B, Verhey FR, Adam JJ, Prickaerts J, Leentjens AF.
    J Neurol Sci; 2006 Oct 25; 248(1-2):259-65. PubMed ID: 16756999
    [Abstract] [Full Text] [Related]

  • 7. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B, Verhey FR, Adam JJ, Weber W, Leentjens AF.
    Clin Neuropharmacol; 2006 Oct 25; 29(5):276-85. PubMed ID: 16960473
    [Abstract] [Full Text] [Related]

  • 8. P300 event-related potentials in de novo Parkinson's disease.
    Graham JS, Yiannikas C, Gordon E, Coyle S, Morris JG.
    Clin Exp Neurol; 1990 Oct 25; 27():89-98. PubMed ID: 2129963
    [Abstract] [Full Text] [Related]

  • 9. Event-related potential and autonomic signs of maladaptive information processing during an auditory oddball task in panic disorder.
    Wise V, McFarlane AC, Clark CR, Battersby M.
    Int J Psychophysiol; 2009 Oct 25; 74(1):34-44. PubMed ID: 19607864
    [Abstract] [Full Text] [Related]

  • 10. Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials.
    Tinazzi M, Del Vesco C, Defazio G, Fincati E, Smania N, Moretto G, Fiaschi A, Le Pera D, Valeriani M.
    Pain; 2008 May 25; 136(1-2):117-24. PubMed ID: 17765400
    [Abstract] [Full Text] [Related]

  • 11. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study.
    Elsinger CL, Rao SM, Zimbelman JL, Reynolds NC, Blindauer KA, Hoffmann RG.
    J Int Neuropsychol Soc; 2003 Nov 25; 9(7):1088-98. PubMed ID: 14738289
    [Abstract] [Full Text] [Related]

  • 12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov 25; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 13. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA.
    Neuropsychologia; 2009 Apr 25; 47(5):1374-81. PubMed ID: 19428401
    [Abstract] [Full Text] [Related]

  • 14. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.
    Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L.
    Arch Neurol; 2004 Aug 25; 61(8):1280-4. PubMed ID: 15313848
    [Abstract] [Full Text] [Related]

  • 15. The effects of apomorphine on attentional processing in Parkinson's disease.
    Růzicka E, el Massioui F, Pillon B, Dubois B, Renault B, Agid Y.
    Sb Lek; 1999 Aug 25; 100(2):85-99. PubMed ID: 11220166
    [Abstract] [Full Text] [Related]

  • 16. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
    Fern-Pollak L, Whone AL, Brooks DJ, Mehta MA.
    Neuropsychologia; 2004 Aug 25; 42(14):1917-26. PubMed ID: 15381022
    [Abstract] [Full Text] [Related]

  • 17. Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.
    Lukhanina EP, Kapustina MT, Berezetskaya NM, Karaban IN.
    Clin Neurophysiol; 2009 Oct 25; 120(10):1852-8. PubMed ID: 19767236
    [Abstract] [Full Text] [Related]

  • 18. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, Arabia G, Pugliese P, Zappia M, Quattrone A.
    Brain Res Bull; 2007 Sep 14; 74(1-3):75-83. PubMed ID: 17683792
    [Abstract] [Full Text] [Related]

  • 19. Effect of cognitive and motor tasks on postural stability in Parkinson's disease: a posturographic study.
    Marchese R, Bove M, Abbruzzese G.
    Mov Disord; 2003 Jun 14; 18(6):652-8. PubMed ID: 12784268
    [Abstract] [Full Text] [Related]

  • 20. Parkinson's disease. Clinical and electrophysiological evaluation.
    Al-Bunyan MA.
    Saudi Med J; 2000 Jan 14; 21(1):72-5. PubMed ID: 11533754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.